Want to see ANNX full AI Analyst Report?
ANNX Stock Chart & Stats
$5.22
$0.06(1.15%)
At close: 4:00 PM EDT
$5.22
$0.06(1.15%)
Day’s Range― - ―
52-Week Range$2.03 - $7.18
Previous CloseN/A
Volume142.64K
Average Volume (3M)4.55M
Market Cap
$840.51M
Enterprise Value$876.28
Total Cash (Recent Filing)$225.03M
Total Debt (Recent Filing)$25.43M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Aug 17, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.22
Shares Outstanding163,842,540
10 Day Avg. Volume4,021,369
30 Day Avg. Volume4,553,715
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)3.68
Price to Sales (P/S)0.00
P/FCF Ratio-4.18
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.00Price Target Upside168.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.96
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
C1q-focused PipelineAnnexon's focused platform targeting complement component C1q is a durable competitive asset: a single mechanism addresses multiple inflammation-driven diseases (neurodegenerative, autoimmune, ophthalmic). That translational breadth can sustain long-term partner interest and multiple indication pathways if clinical proof emerges.
Low Leverage And Equity CushionRelatively low debt and a meaningful equity base provide structural financial flexibility for a clinical-stage biotech. Low leverage reduces near-term solvency risk and preserves optionality to pursue partnerships, licensing, or staged financing rather than distressed outcomes as clinical programs progress.
Governance Continuity And OversightShareholder approval of directors and executive compensation, plus ratification of KPMG, signals governance continuity and strengthened financial oversight. Stable leadership and an established auditor reduce execution and reporting risk, supporting sustained development execution over months ahead.
Bears Say
Pre-revenue With Large Net LossesAnnexon remains historically pre-revenue and is absorbing substantial operating losses. Persistent negative profitability is a structural weakness for durability: without product sales, the company depends on external capital or partnerships to sustain R&D, exposing long-term viability to clinical outcome risk.
High And Accelerating Cash BurnOperating and free cash flow deficits are large and accelerating, materially shortening financial runway absent new financing or partnership revenue. Structurally high burn increases the likelihood of dilutive capital raises within the 2–6 month horizon, constraining strategic optionality and execution cadence.
Expanded Authorized Shares (dilution Risk)The increase in authorized common shares materially expands the company's capacity to issue equity, a structural capital-marketing tool that also raises dilution risk. For a cash-burning, pre-revenue biotech, this enhances the probability that future financing will dilute existing owners if used to plug runway gaps.
Annexon Biosciences News
ANNX FAQ
What was Annexon Biosciences, Inc.’s price range in the past 12 months?
Annexon Biosciences, Inc. lowest stock price was $2.03 and its highest was $7.18 in the past 12 months.
What is Annexon Biosciences, Inc.’s market cap?
Annexon Biosciences, Inc.’s market cap is $840.51M.
When is Annexon Biosciences, Inc.’s upcoming earnings report date?
Annexon Biosciences, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 19 days.
How were Annexon Biosciences, Inc.’s earnings last quarter?
Annexon Biosciences, Inc. released its earnings results on May 07, 2026. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.283 by $0.053.
Is Annexon Biosciences, Inc. overvalued?
According to Wall Street analysts Annexon Biosciences, Inc.’s price is currently Undervalued.
Does Annexon Biosciences, Inc. pay dividends?
Annexon Biosciences, Inc. does not currently pay dividends.
What is Annexon Biosciences, Inc.’s EPS estimate?
Annexon Biosciences, Inc.’s EPS estimate is -0.24.
How many shares outstanding does Annexon Biosciences, Inc. have?
Annexon Biosciences, Inc. has 163,842,540 shares outstanding.
What happened to Annexon Biosciences, Inc.’s price movement after its last earnings report?
Annexon Biosciences, Inc. reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.283. Following the earnings report the stock price went up 3.08%.
Which hedge fund is a major shareholder of Annexon Biosciences, Inc.?
Currently, no hedge funds are holding shares in ANNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Annexon Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.00 (168.20% Upside)
$14.00 (168.20% Upside)
Blogger Sentiment
Bullish
ANNX Sentiment 70%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
104.38%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.25%
Trailing 12-Months
Company Description
Annexon Biosciences, Inc.
Annexon, Inc. (Annexon Biosciences; Nasdaq: ANNX) is a clinical-stage biotechnology company focused on developing therapies that target the classical complement pathway of the immune system, with the goal of treating neurodegenerative, autoimmune, and ophthalmic diseases driven by inflammation and complement-mediated damage. Its pipeline centers on drug candidates designed to inhibit complement component C1q, including ANX005 (an intravenous anti-C1q antibody) and ANX007 (an intravitreal anti-C1q antibody), which have been studied in indications such as Guillain-Barré syndrome and geographic atrophy, respectively.
ANNX Stock 12 Month Forecast
Average Price Target
$14.00
▲(168.20% Upside)
Technical Analysis
Galectin Therapeutics
―
Aldeyra Therapeutics
―
Editas Medicine
―
Alector
―
Neumora Therapeutics, Inc.
―
Ownership Overview
7.11% Insiders
18.73% Mutual Funds
0.46% Other Institutional Investors
57.46% Public Companies and
Individual Investors